RCS - Tiziana Life Science - Tiziana Life Sciences Announces Death of Director
13/01/2022 13:05
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220113:nRSM3631Ya&default-theme=true
RNS Number : 3631Y Tiziana Life Sciences PLC 13 January 2022
Tiziana Life Sciences Announces Death of Director
New York, January 13, 2022 - Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana"),
a biotechnology company enabling breakthrough immunotherapies via novel routes
of drug delivery, today announced that Dr. Thomas Adams passed away on January
9, 2022. He served as a member of Tiziana Life Science's Board of Directors
since February 2021.
Dr. Kunwar Shailubhai, the Company's CEO, commented, "It is with great sadness
that we announce the passing of Dr. Tom Adams. He was a highly valued Director
of the Company and was an inspiration to all of us. Although he joined the
Board a year ago, Dr. Adams had been involved with Tiziana over a number of
years. He will be missed not only as a business colleague, but also as a
friend. We extend our deepest sympathies to the entire Adams family."
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing
breakthrough therapies using transformational drug delivery technologies to
enable alternative routes of immunotherapy. Tiziana's innovative nasal, oral
and inhalation approaches in development have the potential to provide an
improvement in efficacy as well as safety and tolerability compared to
intravenous (IV) delivery. Tiziana's two lead candidates, intranasal
foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK
inhibitor, have both demonstrated a favorable safety profile and clinical
response in patients in studies to date. Tiziana's technology for alternative
routes of immunotherapy has been patented with several applications pending
and is expected to allow for broad pipeline applications.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAEAEFDFANAEFA